Renal Cell Carcinoma

In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma.

In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib.

Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved.

Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment.

The Meet-URO score combines inflammatory and clinical markers to predict response to nivolumab.

In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy.

Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability.

Stereotactic radiotherapy for oligoprogressive tumors while on oral systemic therapy delays time to treatment switch.

A 14-mg starting dose of lenvatinib did not improve tolerability and had numerically worse efficacy than the approved 18-mg dose.

In a phase 2 trial, cabozantinib tolerably improved outcomes in patients pretreated with immunotherapy.